A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

NCT06433557 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Sponsor

Ascendis Pharma Growth Disorders A/S